RecruitingPHASE1, PHASE2NCT03331198
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Studying B-cell chronic lymphocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
- Principal Investigator
- Bristol-Myers SquibbBristol-Myers Squibb
- Intervention
- JCAR017 (lisocabtagene maraleucel)(biological)
- Enrollment
- 320 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2027
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- University of Alabama Birmingham, Birmingham, Alabama, United States
- Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
- City of Hope, Duarte, California, United States
- City Of Hope, Duarte, California, United States
- UC San Diego Moores Cancer Center, La Jolla, California, United States
- University Of California San Diego Moores Cancer Center, La Jolla, California, United States
- Local Institution - 0059, Los Angeles, California, United States
- University of California, Los Angeles, Los Angeles, California, United States
- Local Institution - 0010, San Francisco, California, United States
- University of California, San Francisco, San Francisco, California, United States
- Colorado Blood Cancer Institute, Denver, Colorado, United States
- Local Institution - 0110, Newark, Delaware, United States
- Georgetown University Medical Center, Washington D.C., District of Columbia, United States
- Local Institution - 0085, Washington D.C., District of Columbia, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03331198 on ClinicalTrials.govOther trials for B-cell chronic lymphocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07194980Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaFred Hutchinson Cancer Center
- RECRUITINGEARLY PHASE1NCT07428707Immune Profiling of CLL/SLL Treated With First-Line PirtobrutinibNational Heart, Lung, and Blood Institute (NHLBI)
- RECRUITINGPHASE4NCT07218341A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaEli Lilly and Company
- RECRUITINGPHASE1NCT06859008Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCity of Hope Medical Center
- RECRUITINGPHASE2NCT07271667A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesCuris, Inc.
- RECRUITINGPHASE2NCT07014917Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLLZulfa Omer
- RECRUITINGPHASE2NCT06958705Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor MonotherapyThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE1, PHASE2NCT07052695Mosunetuzumab for CLL MRD ClearanceInhye Ahn